Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

被引：2361

作者：

Degterev A. ^{[1
]}

Huang Z. ^{[2
]}

Boyce M. ^{[1
]}

Li Y. ^{[1
]}

Jagtap P. ^{[3
]}

Mizushima N. ^{[4
]}

Cuny G.D. ^{[3
]}

Mitchison T.J. ^{[5
]}

Moskowitz M.A. ^{[2
]}

Yuan J. ^{[1
]}

机构：

[1] Department of Cell Biology, Harvard Medical School, Boston, MA, 02115

[2] Stroke and Neurovascular Regulation Laboratory, Massachusetts General Hospital Harvard Medical School, Charlestown, MA, 02129

[3] Laboratory for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair, Brigham & Women’s Hospital and Harvard Medical School, Cambridge, MA, 02139

[4] Department of Bioregulation and Metabolism, The Tokyo Metropolitan Institute of Medical Science, Tokyo, 113-8613, 3-18-22 Honkomagome, Bunkyo-ku

[5] Department of Systems Biology, Harvard Medical School, Boston, MA, 02115

来源：

Nature Chemical Biology | 2005年 / 1卷 / 2期

关键词：

D O I：

10.1038/nchembio711

中图分类号：

学科分类号：

摘要：

The mechanism of apoptosis has been extensively characterized over the past decade, but little is known about alternative forms of regulated cell death. Although stimulation of the Fas/TNFR receptor family triggers a canonical ‘extrinsic’ apoptosis pathway, we demonstrated that in the absence of intracellular apoptotic signaling it is capable of activating a common nonapoptotic death pathway, which we term necroptosis. We showed that necroptosis is characterized by necrotic cell death morphology and activation of autophagy. We identified a specific and potent small-molecule inhibitor of necroptosis, necrostatin-1, which blocks a critical step in necroptosis. We demonstrated that necroptosis contributes to delayed mouse ischemic brain injury in vivo through a mechanism distinct from that of apoptosis and offers a new therapeutic target for stroke with an extended window for neuroprotection. Our study identifies a previously undescribed basic cell-death pathway with potentially broad relevance to human pathologies. © 2005, Nature Publishing Group. All rights reserved.

引用

页码：112 / 119

页数：7

共 37 条

[1] Degterev A., Boyce M., Yuan J., A decade of caspases, Oncogene, 22, pp. 8543-8567, (2003)
[2] Wallach D., Et al., Tumor necrosis factor receptor and Fas signaling mechanisms, Annu. Rev. Immunol., 17, pp. 331-367, (1999)
[3] Vercammen D., Et al., Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways, J. Exp. Med., 188, pp. 919-930, (1998)
[4] Matsumura H., Et al., Necrotic death pathway in Fas receptor signaling, J. Cell Biol., 151, pp. 1247-1256, (2000)
[5] Schulze-Osthoff K., Krammer P.H., Droge W., Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death, EMBOJ, 13, pp. 4587-4596, (1994)
[6] Holler N., Et al., Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule, Nat. Immunol., 1, pp. 489-495, (2000)
[7] Chan F.K., Et al., A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses, J. Biol. Chem, 278, pp. 51613-51621, (2003)
[8] Kawahara A., Ohsawa Y., Matsumura H., Uchiyama Y., Nagata S., Caspase-independent cell killing by Fas-associated protein with death domain, J. Cell Biol., 143, pp. 1353-1360, (1998)
[9] Khwaja A., Tatton L., Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway, J. Biol. Chem., 274, pp. 36817-36823, (1999)
[10] Lin Y., Et al., Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation, J. Biol. Chem., 279, pp. 10822-10828, (2004)

← 1 2 3 4 →